Overview

A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy

Status:
Completed
Trial end date:
2016-07-26
Target enrollment:
Participant gender:
Summary
Examine safety and immunological response for ASP4070 when vaccinated in patients with pollen allergy
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Immunomic Therapeutics, Inc.
Treatments:
Vaccines